Decision Support in North Carolina

Owlstone Medical is a UK-based biotechnology company pioneering breath biomarker analysis for non-invasive disease detection and precision medicine. The company develops Breath Biopsy® technology and related research products and services that enable comprehensive analysis of volatile organic compounds (VOCs) from multiple sample types, ranging from in vitro cell culture to human breath samples. Clinical applications span oncology (lung cancer, multi-cancer early detection), respiratory disease (cystic fibrosis, Pseudomonas aeruginosa detection), gastrointestinal disorders, liver disease, and microbiome analysis. Owlstone's Breath Biopsy VOC Atlas® is a proprietary database of volatile organic compound biomarkers supporting research and clinical validation. The company collaborates with major academic medical centers (Mayo Clinic, Cleveland Clinic, Brigham and Women's Hospital, NHS), pharmaceutical partners (AstraZeneca, Boehringer Ingelheim, MedImmune), and cancer research organizations (Cancer Research UK). Recent funding includes a $49.1 million ARPA-H award for developing at-home multi-cancer early detection tests targeting Stage I detection of 30+ solid tumors, and a Cystic Fibrosis Foundation investment for breath testing of bacterial infections. Owlstone maintains an active FDA research collaboration agreement for developing analytical methods to identify specific chemicals in gaseous mixtures. The company is positioned in the diagnostic software and decision-support space, providing tools for biomarker identification and clinical validation rather than manufacturing traditional medical devices.

Calla Health Foundation is a medical device company focused on improving women's access to cervical cancer prevention and screening, particularly in low-resource settings. The organization develops portable, affordable diagnostic imaging technologies and AI-driven decision support systems designed to democratize gynecological examination and cancer prevention. Their product suite includes the Pocket Colposcope (a portable, low-cost video colposcope for cervical tissue examination), the Callascope (a speculum-free cervical imaging device enabling self-screening or provider-assisted insertion), and CARE (an AI algorithm for cervical pre-cancer risk assessment). The company's innovations enable midwives and community health workers to perform point-of-care screening and "see-and-treat" management paradigms without requiring traditional hospital infrastructure or specialized physician expertise. FDA-cleared and clinically validated in multiple low- and middle-income countries.

Laboratory Corporation of America Holdings (Labcorp) is a global leader in laboratory services headquartered in Burlington, North Carolina. Operating in approximately 100 countries with over 70,000 employees, Labcorp performs more than 700 million tests annually and generates $13.01 billion in revenue. The company provides comprehensive clinical diagnostics, drug development support, and specialized testing including oncology, rare diseases, and genomic sequencing. Labcorp's integrated platform connects diagnostics to biopharma development, supporting healthcare providers, researchers, and investigators. Key offerings include AI-powered diagnostic assistance tools, real-world data platforms for drug development, genetic testing services (including Invitae), nonclinical research, central laboratory services, and clinical trial support. The company serves patients, healthcare providers, health systems, managed care organizations, and biopharmaceutical companies. Over 75% of new drugs approved by the FDA have been supported by Labcorp's services.

Myocardial Solutions develops MyoStrain®, a proprietary cardiac software platform that leverages MRI imaging data to quantify myocardial strain and assess cardiac function. The platform is designed to enable early detection and proactive management of cardiac dysfunction in at-risk and asymptomatic patient populations. MyoStrain performs rapid (approximately 10-minute), quantitative assessment of myocardial function using segmental intra-myocardial strain analysis. The software supports clinical decision-making in cardiology and cardio-oncology applications, helping physicians identify subtle changes in cardiac performance before symptoms manifest, thereby enabling earlier intervention and improved patient outcomes. The company targets standardization of preventative cardiac care delivery within healthcare systems, supporting enhanced clinical efficiency, cost reduction, and improved reimbursement models. Products are supported by clinical presentations, peer-reviewed publications, and conference presentations demonstrating clinical validation and utility.

PeriGen is a perinatal healthcare software company with over 27 years of experience developing solutions for labor and delivery management. The company specializes in maternal-fetal surveillance and early warning systems designed to prevent complications during childbirth. PeriGen's flagship platform, PeriWatch, includes advanced fetal heart rate pattern analysis, automated risk detection, and clinical decision support tools. The company's solutions integrate with electronic fetal monitoring systems and electronic medical records to provide real-time data analysis and clinician alerts. PeriWatch Vigilance uses FDA-cleared machine learning algorithms to continuously interpret fetal heart rate patterns and detect labor progress anomalies. Additional offerings include centralized monitoring command centers, mobile applications for clinician access, quality reporting dashboards, and automated safety threshold notifications. PeriGen serves over 500 hospitals across the United States and Canada, supporting approximately 750,000 births annually. The company emphasizes responsible AI implementation that complements rather than replaces clinical expertise, with published outcomes data demonstrating impact on maternal and fetal safety.